Nanobiotix S.A. (NBTX) Form 6-K — Sep 14, 2026
Nanobiotix announced complete full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer, presented at the IASLC 2026 World Conference on Lung Cancer. All 24 patients completed treatment with no dose-limiting toxicities and no Grade 3 or higher adverse events related to the drug or the injection procedure. Efficacy was encouraging: at a median follow-up of 12 months, the one-year locoregional control rate was 79%, one-year local progression-free survival was 61%, and one-year overall survival was 70%, achieved at a substantially lower re-irradiation dose than patients' prior course of radiotherapy.
Key figures
- Data cutoff
- August 2026
- Study phase
- Phase 1 (dose-escalation and expansion complete per protocol)
- Median OS months
- 14.8
- Patients treated
- 24
- Median LPFS months
- 13.6
- Median followup months
- 12
- Recommended phase2 dose
- 33% of gross tumor volume
- Dose limiting toxicities
- 0
- One year overall survival
- 70%
- One year locoregional control
- 79%
- Grade3 radiotherapy related aes
- 33% (n=8)
- Grade5 radiotherapy related aes
- 8% (n=2)
- Grade3 or higher aes related to jnj1900
- 0
- One year local progression free survival
- 61%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.